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2ABSTRACT
When formulated as liquid dosage forms, therapeutic proteins often show instability
during handling as a result of chemical degradation. Solid formulations are frequently
required to maintain protein stability during storage, transport and upon
administration. Herein we highlight current strategies that have been developed to
formulate pharmaceutical proteins in the solid form. An overview of the physical
instabilities which can arise with proteins is first described. The mechanism,
challenges and applications of the key solidification techniques of crystallisation,
freeze-drying and particle forming technologies are subsequently discussed. Examples
of current commercial products are provided to give an insight into the medical
applications of this science: these include NPH-insulin crystal suspensions, freeze-
dried monoclonal antibodies and leuproride polylactide-co-glycolide microparticles.
Finally, future perspectives in solid state protein formulation are described.
3INTRODUCTION
Pharmaceutical proteins form a major class of medicines including therapeutic
enzymes, peptide hormones, cytokines, monoclonal antibodies (mAbs) and vaccines.
They are used to treat and prevent a wide range of diseases. New expression systems
and more efficient downstream processing have in recent years significantly improved
the manufacture of therapeutic proteins. Protein instability often contributes to
variations in the manufactured product, and is a major concern in the final dosage
form. Retaining the native configuration in protein formulations is of vital importance
in maintaining their function. Loss or change in structure may result in the loss of
dose reproducibility and may increase the propensity for deleterious side effects (e.g.
increased immunogenicity).
In this review, we consider the range of platforms which have been used to
manufacture therapeutic proteins in stable solid-state dosage forms. First, some
background information on the physical instability of therapeutic proteins is provided.
A range of solidification techniques including crystallisation, freeze-drying and
particle forming technologies are then discussed in terms of their underlying
principles, limitations, product stability and applications. Examples of commercial
products containing proteins solidified by each method are given. Future opportunities
and challenges in stabilising proteins in the solid state are also considered.
41. POTENTIAL PHYSICAL INSTABILITIES IN PROTEIN
THERAPEUTICS
Biologically active proteins will have a unique native three-dimensional flexible
structure, typically known at the tertiary or folded structure, that allows them to
undergo specific interactions with other molecules in biochemical reactions [1-2].
Protein tertiary structure is maintained by non-covalent interactions, where generally
the more insoluble amino acid residues are less solvent accessible and much of the
thermodynamic stability of the folded structure is maintained by the hydrophobic
effects that are possible in the folded state [3–5]. The non-covalency of the tertiary
structure means that changes in the chemical (e.g. pH or ionic strength) or physical
(e.g. agitation or shear) environments can lead to loss of tertiary structure (e.g.
misfolding, aggregation, denaturation) [1] .
Under physiological conditions, protein folding is a complex post-translational
process that has evolved for proteins to attain their biologically active form. Often
proteins also need to be secreted from the intracellular environment. While the
information encoded in the amino acid sequence of the polypeptide chain [2] dictates
the most stable tertiary structure of a protein, during the folding process there are
many possibilities for misfolding. Such misfolded structures may occupy
thermodynamic energy states that inhibit formation of the correctly folded protein.
Many relevant proteins of therapeutic interest tend to be potent and to be
physiologically available only in small amounts. Maintaining the tertiary structure is
therefore of critical importance to be able to utilise protein therapeutics effectively.
When pharmaceutical proteins are placed in a non-physiological environment or
exposed to physicochemical stress during handling or storage, the tertiary structure
can alter to adapt to the changing environment [1,6]. These structural changes can
result in formulations containing combinations of structural variants or intermediate
species; these will have different physical properties including solubility, surface
activity or propensity to aggregate [7]. Changes in protein conformation may result in
the formation of insoluble precipitates, or lead to a denatured form [1,2,8] (see Figure
1). Subtle changes in the tertiary structure of a protein can lead to the formation of
intermediate conformational states that have an increased tendency to interact with
5other protein molecules to form aggregates. The aggregated molecules may be
capable of de-aggregating to a monomeric intermediate form but more often undergo
further conformational changes to form irreversible aggregates [1,9,10]. Considerable
effort by pharmaceutical companies and regulators is focused on characterising
protein aggregates and minimising the processes that result in their formation.
Figure 1: A schematic illustration of the different physical forms a protein can adopt.
Denaturation can occur as the result of a loss of tertiary and then secondary structure.
As with misfolding and aggregation, denaturation will also result in the loss of protein
function. While the chemical composition [10] of the protein remains the same, its
function will be compromised so that providing a reproducible dose is not possible.
All these processes may potentially result in the protein becoming immunologically
more toxic. This is a situation that must be avoided, especially with replacement
therapeutic proteins that are used to supplement an endogenous protein (e.g.
erythropoietin). Loss of tertiary stucture can be caused by many different conditions,
such as an increase in temperature, change in pH, the addition of organic solvents
[7,10], freezing and thawing [11] or in the presence of certain chemicals such as urea
or guanidinium hydrochloride [9-10].
1.1 PROTEIN AGGREGATION
Generally therapeutic protein species such as dimers, oligomers or multimers (as
opposed to a single unit monomeric form) are referred to as “aggregates” [14].
Aggregation often results from non-covalent interactions between normally solvent
inaccessible residues. Bond formation (e.g. intermolecular disulfide bond formation)
between protein molecules can also drive aggregation. Reversible aggregates are
6frequently formed when the protein concentration is above its equilibrium solubility
[15]. Under such conditions proteins tend to form insoluble aggregates, which can
sometimes be returned to their native monomeric form when the concentration is
decreased below the solubility limit [1,14]. Irreversible aggregates generally form as a
result of non-covalent interactions (such as hydrogen bonding, hydrophobic or
electrostatic interactions) or covalent bonding through disulfide bridges or dityrosine
formation [6,14,16]. Protein aggregation can cause an immune response to be
stimulated in vivo [14-15]. The deposition of proteins as amyloids fibrils is the
underlying pathogenesis for more than 20 degenerative diseases including Parkinson’s
and Alzheimer’s [19]. Understanding and controlling protein aggregation is thus a
major challenge for the biopharmaceutical industry.
2. STRATEGIES TO IMPROVE PROTEIN STABILITY IN THE SOLID
STATE
Therapeutic proteins in liquid formulations are susceptible to loss of tertiary structure
during shipping and storage [20]. The presence of water can also facilitate chemical
degradation reactions which change the covalent structure of the protein [21].
Hydrolytic processes including deamidation, oxidation and aspartate isomerisation
may lead to aggregation, denaturation, and loss of activity [10,22]. Ideally, the
development of stable liquid formulations would be the optimum solution to these
problems. However, this is very frequently not possible. In such cases, the removal of
water to give a solid protein formulation can improve protein stability during storage
[23–25], and can also significantly lower the rate of hydrolytic reactions. Much effort
is focused at removing the need for a cold chain, so that protein therapeutics can
better withstand storage at ambient conditions: solid formulations can also be
advantageous here. The following sections discuss the various strategies that have
been considered to stabilise the protein in the solid state including crystallisation,
freeze-drying, and particle forming technologies. These solid state formulations will
require reconstitution with water prior to administration, which can be
disadvantageous particularly where high injected volumes are required. However, the
use of solid-state formulations, particularly freeze dried formulations has led to a
number of commercially available medicines, and to very significant improvements in
the health of many individuals.
72.1 PROTEIN CRYSTALLISATION
Proteins are generally amorphous materials, meaning that in the solid state there is no
regular arrangement of the macromolecular units. There is thus no lattice enthalpy,
and as a result proteins in the solid state are normally highly prone to interact with
denaturants [26]. In contrast, crystalline solid state forms of macromolecules are
resilient to chemical denaturation because of their lattice enthalpy: the existence of a
regular arrangement of molecules and intermolecular bonds in the solid state enhances
stability [27]. The development of crystalline forms of therapeutic proteins is thus a
potential route to increase their stability. In addition, crystallisation may remove the
requirement for further downsteam purification, therefore minimising production
costs [28]. The crystal phase diagram (Figure 2) is a useful tool to understand crystal
formation and to design a crystallisation process [29]. Typically, a crystallisation
process will be undertaken by adding an amorphous solid state protein to a solvent.
The protein solutes diffuse from the solid to the bulk solution, and when the solution
concentration reaches a certain point nuclei are generated. These act as “seeds” for
further crystallisation. The number of nuclei will increase in number when the
concentration of protein approaches the supersolubility curve (see Figure 2). The
protein concentration is spontaneously decreased upon nucleation, which shifts the
system from the supersaturated region to the metastable zone (II) where nuclei
‘growth’ occurs. Crystal formation proceeds as further protein molecules are
deposited on the seeds, eventually yielding visible crystals [26]. Amorphous
precipitation (IV) may occur beyond the nucleation zone (III) [30]. In order for a
successful crystallisation process to occur, all this must take place without the protein
tertiary structure being altered.
Key term
Lattice enthalpy: A measure of the strength of the intermolecular bonds
between macromolecules in the solid state.
8Figure 2: A schematic crystal phase diagram illustrating the (I) undersaturated region, (II) metastable
zone, (III) nucleation zone and (IV) amorphous precipitation region. Adapted from Ref. [29].
A range of parameters (e.g. pH, temperature, metal ions, precipitants) can be adjusted
to facilitate crystallisation. Additives may also be employed to drive the process
forward. For instance, insulin is negatively charged at physiological pH, and forms a
complex with divalent ions in the pancreas. This suggests that such ions can be used
to aid the formation of protein crystals [31,32]. The addition of phenolic ligands or
high chloride concentrations also assist crystallisation [33,34]. This highlights a role
for phenolic derivatives (e.g. m-cresol and methyl paraben) in insulin preparations
beyond simply acting as preservatives. Rhombohedral insulin crystals, for instance,
were obtained with 0.25 % aqueous phenol at pH 5.5, while monoclinic crystals were
formed with 1% phenol at pH 6.49 [35,36]. These results demonstrate the importance
of the crystallisation conditions (e.g. pH and phenol ligand concentration) on the
interaction of the insulin molecules and the resultant crystal habit.
Insulin is rather unique in being a small protein which forms stable hexamers, but is
unstable as fibrils. However, other proteins have also successfully been crystallised.
Spherical crystals of recombinant human interferon-α-2b (rhIFN) were prepared by 
adding zinc acetate to a solution of the protein; see Figure 3(a). The extent of crystal
recovery is proportional to the zinc acetate : rhIFN ratio used in processing [37]. X-
9ray diffraction data clearly demonstrated distinct Bragg reflections when rhIFN was
reacted with a 12 : 1 mol ratio of zinc acetate, confirming that crystals had been
formed: this is depicted in Figure 3(b) and can be compared with the amorphous halo
seen in the diffraction pattern of the native protein. In another study, Hebel et al.
demonstrated the successful crystallisation of antibody fragments (FabC225) in a
stirred tank [38]. For a more detailed treatment of the crystallisation of bioactive
protiens the interested reader is directed to a recent review [28].
(a)
(b)
Figure 3: Characterisation data for spherical rhIFN crystals formed after reaction with Zn acetate. (a)
Scanning electron micrographs of i) native rhIFN and ii) rhIFN crystals, and (b) X-ray diffraction
patterns of i) native rhIFN, ii) rhIFN crystals and iii) zinc acetate. Reproduced with permission from
ref. [37]. Copyright Shenyang Pharmaceutical University 2013.
For small molecule drugs, nucleation is considered to be the rate limiting step in
crystallisation. However, the mechanism of protein crystal formation is rather more
complex, and has not to date been fully elucidated. This stems from the increased size
and complexity of macromolecules, which means they are less likely to pack together
(i) (ii)
(i)
(ii)
(iii)
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as long-range ordered systems. The size, length and flexibility of amino acids also
influence lattice formation [39]. In addition, the translational and rotational diffusion
of protein molecules in solution is crucial for nucleation. The former can bring two
macromolecules into intimate contact [40], which is explained by the Smoluchowski
equation (Equation 1) :
k஽ = 8ߨܦݎ (Equation 1)
In Equation 1, kD is the diffusion rate constant for a second order bimolecular
reaction, D is the translational diffusivity and r is the radius of the molecules
colliding. The rate of protein diffusion is slow (much less than that for small
molecules). It is clear from this that steric hindrance influences molecular diffusion,
and is likely to complicate protein lattice formation.
This diffusion process can be simulated for proteins using Brownian dynamics, under
the assumption that two spherical proteins have to reorient the complementary parts
of their structures (“patches”) in the correct configuration prior to association [41].
Nanev has devised a patch model to describe protein nucleation, depicted in Figure 4
[40]. In brief, the surface patches through which two protein molecules can interact
are considered to be symmetrically distributed on spherical protein. The
complementary patches on two molecules must be paired in order to form clusters of
molecules. The model suggested that the pattern of patches on a protein’s surface is
likely to have a significant impact on the nucleation process [42]. The energy barrier
to nucleation and the homogeneity of the nuclei forming are also important to
consider [43]. In practical terms therefore, to achieve successful protein crystallisation
we need to understand their structural biology, and extent of purity. Those
technologies have been reviewed elsewhere [29] and may be applied to formulate
crystalline proteins. However, manufacturing issues such as batch to batch
reproducibility and aseptic manufacture also need to be addressed to achieve large
scale production [28,38].
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Figure 4: An illustration of the contact patch model for protein nucleation (not to scale). 4.1a) a linear
protein cluster is formed by pairing two complementary patches (A and B) in one direction. 4.1b) The
spherical protein has to reorient to match patches A and B prior to association, giving rise to the growth
of one dimensional in “zigzag” clusters. 4.2 The protein shown here is more complex, with additional
patches C and D which can interact to form a 2D-cluster. 4.3 A three-dimensional aggregate is formed
when complementary patches are paired in all directions: A and B, C and D, E and F (patch F is behind
E). Adapted from refs. [43,44].
Although it is hypothesised that the generation of crystalline protein materials can
enhance stability [27], there are other complicating factors that may counteract this
effect. Huus et al. investigated the thermal stability of insulin complexes at 37 ºC
[45]. Their results demonstrated that a zinc-insulin complex with one Zn2+ per
hexamer (0.1 mM Zn2+ to 0.6 mM insulin) can prevent insulin from B3 deamidation if
the Zn coordinates at a specific site. However, Zn2+ itself may cause the AsnB3
residues to become more electrophilic and subject to processes such as dimerization.
This issue, along with that of hexamer fragmentation, is alleviated when the hexamer
is stabilised with phenol. Differential scanning calorimetry data from the same study
indicated that anionic ligands could reinforce zinc affinity for the protein complex.
X
Y
Z
4.1 a)
4.1 b)
4.2
4.3
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Commercial application: NPH-insulin crystals
Insulin is a peptide hormone secreted by the β-cells of the pancreas, and is vital for 
the regulation of blood sugar levels. Artificial insulin formulations comprise one of
the most successful biopharmaceutical products developed to date, and the
development of insulin replacement products has been hugely successful in the
management of both type I and II diabetes.
Native insulin contains 51 amino acids arranged into two polypeptide chains: the A-
chain contains 21 residues and the B-chain 30 residues. The chains are linked with
three disulfide bonds, two inter-chain (A7-B7 and A20-B19) and one intra-chain (A6-
A11). The structure of insulin is given in Figure 5. Genetic engineering has been
heavily exploited to modify the insulin sequence in order to tailor the
pharmacokinetic profile of the molecule, as shown in Table 1 [46,47].
Table 1: Genetically engineered insulin therapies approved in the clinic. Adapted from refs. [46,47].
Product Structure modification Duration of
action
Manufacturer
Lispro B28-B29 proline-lysine inversion Short-acting Eli Lilly
Aspart B28 aspartic acid substitution Short-acting Novo Nordisk
Levemir B30 depletion and B29 myristoyl lysine Long-acting Novo Nordisk
Glulisine B3 lysine, B29 glutamic acid substitution Rapid-acting Aventis
Pharmaceuticals
Lantus A21 glycine substitution and B chain
elongation by two arginines
Long-acting Aventis
Pharmaceuticals
Degludec B30 depletion and B29 acylation with
hexadecandioic acid via γ-L-glutamic linker 
Long-acting Novo Nordisk
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Figure 5: The native human insulin peptide sequence. The dashed boxes illustrate the segments of the
sequence which have been genetically engineered in commercially-available products.
Of all the insulin products on the market one, neutral protamine hagedorn (NPH)
insulin, is prepared by crystallisation. This is based on work by Krayenbuhl and
Rosenberg in the 1930-40s. These authors successfully co-crystalised an insulin-zinc
solution with protamine at neutral pH using the isophane ratio [48]. Protamine is a 4
kDa basic peptide predominantly comprising Arg residues. It is isolated from the
sperm of chum salmon [49]. Tetragonal insulin crystals containing two zinc ions, the
insulin hexamer and one protamine in the unit cell were formed at pH 7.3 [50]. It was
thought that the hydrophobic interaction of protamine with the insulin AsnB3 residue
possibly stabilises the N-terminus of the B-chain, although Norrman et al. ascertained
that the effect stems from the fact that protamine neutralises the overall charge of
insulin, rather than specific binding [51].
NPH formulations are known as premixed insulin suspensions. The marketed product
contains a mixture of isophane insulin (i.e. the insulin : proteamine complex) and
soluble insulin. A range of formulations exists containing the two components at
various ratios. The aim of the medicine is both to deliver intermediate acting insulin
and act as a sustained release formulation to extend insulin release and absorption.
The duration of action of the NPH insulin is twice as long as regular insulin [52].
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Upon subcutaneous injection, zinc and other ligands (e.g. phenol derivatives and
anions) from the formulation are transported into solution as a result of the dilution
effect [53]. This followed by insulin diffusion from the formulation into solution. The
loss of zinc and other ligands destabilizes the insulin : protamine complex, thus
breaking the hexamer into dimers and monomers.
The principles underlying the function of the NPH medicine have been further
exploited in insulin degludec, a new ultra-long acting basal insulin. With this system,
the rapid loss of phenol upon injection contributes to the association of multiple
hexamers [47]. The complex then breaks into dimers and monomers when zinc slowly
diffuses into the solution. As a result, insulin degludec has a plasma half-life of 25
hours [54].
2.2 FREEZE-DRYING
Freeze-drying is used widely in the pharmaceutical industry for preparing parenteral
dosage forms. Protein formulations are often freeze dried since it is frequently not
possible to prepare stable liquid formulations. Though freeze-drying is expensive, it
has several advantages in that it does not require a terminal sterilisation step,
maintains a particle-free state much more easily than other methods, can be relatively
easily scaled up, and has high recovery yields [55]. Although liquid dosage forms of
proteins in ready-to-use syringes are desirable because they avoid the need for
reconstitution and are more easy to administer to the patient, proteins in such
formulations are susceptible to hydrolysis-mediated loss of tertiary structure during
storage [20]. This issue may be overcome by the removal of water through freeze-
drying. However, some residual water is essential for the maintenance of a protein’s
tertiary structure [56] and thus it is critical to optimise the formulation of each protein
with excipients that cause minimal disruption of its native structure on freeze-drying.
Key term
Isophane ratio : The molar ratio of protamine and insulin forming a complex
with no free protamine or insulin in the supernatant.
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Great care must also be taken to consider the phase interfaces which arise during the
process, and on which proteins may unfold.
Freeze-drying comprises three steps: freezing, primary drying, and secondary drying.
As shown in Figure 6, the freezing cycle (I-II) cools the product until it completely
solidifies and both adsorbed and bound water crystallise. During crystallisation, the
temperature may rise as a result of the latent heat associated with this process [57].
The rate of cooling affects the size and type of ice crystals formed, which can in turn
affect the primary and secondary drying rates. If the rate of cooling is rapid, smaller
ice crystals are formed, while slow rates of cooling yield large crystals.
Subsequently, primary drying (Figure 6, II-III) removes the frozen or unbound water
through the process of sublimation, in which ice is directly transformed to water
vapour under vacuum. The frozen specimen is placed upon a shelf in a temperature-
controlled chamber, and water vapour sublimes out of the solid state. The vapour is
subsequently solidified on a condenser maintained at a lower temperature than the
shelf. This sublimation process results in the formation of pores in the solid product,
the size of which are dependent on the size of the initial ice crystals. Smaller pores
cause higher resistance to water vapor flow, thus decreasing the sublimation rate,
increasing the primary drying time, and rendering the process less efficient. This
phenomenon is also referred to as dried layer resistance [55,58–61].
The driving force for sublimation, Gs, is provided by the vapour pressure difference
between the ice front in the solid product and the surface of the condenser on which
sublimed water is collected. Vapour pressure is inversely proportional to temperature,
and hence the temperature difference between the ice front and the condenser surface
is key to successful primary drying. The drying chamber pressure is always
maintained below the saturation vapour pressure of ice at the operating temperature
[62]. The fill depth and geometry of the vial used for drying can also affect the
product temperature and primary drying time (they affect the surface area of the
formulation being dried) [62], as do the manner in which it is mounted in the drying
chamber [63]. Primary drying is the longest step in the freeze-drying of
biopharmaceutical products, and is therefore economically important. A higher shelf
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temperature for primary drying results in a faster process, favoured for economic
reasons [60]. Hence, it is important to optimise the shelf temperature for primary
drying to ensure a process which is both economical and efficacious.
Figure 6: A schematic diagram illustrating the three cycles in freeze-drying processes: (I-II) freezing,
(II-III) primary drying, (III-IV) secondary drying. Adapted from ref. [57].
In secondary drying (Figure 6, III-IV), the water remaining after primary drying is
removed by diffusion. Secondary drying is typically carried out at a temperature much
higher than primary drying, but for a much shorter period of time [60]. At the end of
primary drying, typically 10 – 20 % residual water remains. Secondary drying reduces
the moisture levels to 1 – 2 % or less. The idea underlying this process is that
reducing the water content further will improve the storage stability of proteins
[55,60]. However, caution must be applied because in secondary drying, while
attempting to remove bound water, it is possible that hydrogen bond imbalances can
be introduced and/or the native protein conformation disturbed. This can in turn result
in reversible or irreversible folding [25].
The freezing rate can also affect protein structure. It has been reported that rapid
freezing resulted in an increase in insoluble aggregate formation and a decrease in
monomer content for the human growth hormone (hGH). This was believed to be a
result of surface denaturation occurring at interfaces between the protein and very
small ice crystals [64]. Freezing a protein solution generates an ice-water interface,
I II III IV
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and proteins can get adsorbed onto this causing disrupting of their native folding state.
The concomitant loss of secondary and tertiary structure can subsequently result in
surface-induced denaturation [65]. A number of proteins (e.g. lactose dehydrogenase,
lysozyme) are cold-labile, and undergo unfolding on exposure to sub-ambient
temperatures. The tertiary structure of such molecules may result in denaturation
independent of the ice/water interface.
Slow freezing has the potential to increase the damage to proteins because as the
water crystallises, there is an increased chance that phase separation may occur. The
latter is a kinetic process and slow freezing provides sufficient time to allow it to
occur [59,66]. Hence, the freezing rate is critical and a moderate cooling rate of
1 ºC / min is recommended if the formulation is prone to phase separation [60]. This
rate leads to a moderate ice surface area, while providing reasonably fast freezing.
The effects of cooling rate are summarised in Table 2.
Table 2: The effect of cooling rate on freeze- drying (Adapted from [62] ).
Excipients can be added to protect the protein from the freezing and drying stresses
imposed during lyophilisation. The most commonly used stabilising excipients are
sugars, polymers and surfactants. Inspiration is taken from nature here: most
anhydrobiotic organisms have adapted a similar strategy of survival, by synthesising
and accumulating trehalose and sucrose [67]. Such sugars can replace the monolayer
of water usually hydrogen bonded to the surface of protein molecules, thereby helping
to preserve the native structure [63]. Disaccharides are thus widely used in protecting
a protein from freezing and drying stresses. A number of theories have been put
forward to explain the excipient-mediated stabilization of proteins in the solid state
including the roles of glass formation, water replacement, and hydrogen bonding
between excipients and proteins [58,68]. Spectroscopic studies have shown that water
replacement by excipients during dehydration better preserves the tertiary structure of
proteins in the solid state and during the freeze drying process [69–71]. When the
Cooling
rate
Ice Nucleation
rate
Number of
ice crystals
Size of ice
crystals
Ice sublimation
time
Low Low Small Large Shorter
High High Large Small Longer
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protein is trapped in the amorphous state, the viscosity of the matrix is very high, and
physical and chemical processes are essentially halted [58,71,72].
A range of excipients including albumin [73–75], dextran [73,76–78], polyvinyl
pyrrolidone (PVP) [75] and polyethylene glycol (PEG) [79–81] have been used as
stabilising excipients in freeze-drying. These are selected by virtue of their ability to
introduce steric hindrance to protein-protein interactions, and increase solution
viscosity (and glass transition temperature) such that protein structural movement is
limited [58]. Alternatively, they may simply act as bulking agents to increase the
pharmaceutical elegance of the product [82] and ensure rapid, controlled and
reproducible reconstitution. Protein denaturation, aggregation or instability due to
partial unfolding can be caused by their adsorption at the surfaces presented during
freeze-drying [58,82]. Surfactants (e.g. polysorbate 20 or 80) [83,84] can ameliorate
these issues, and thus are often used in freeze-dried formulations. Buffers added to the
formulation must be carefully selected such that they do not crystallise during
freezing: the selective crystallisation of buffer salts can cause pH changes, leading to
degradation and instability of proteins [85–87].
Commercial application: Monoclonal Antibodies (mAbs)
IgG-based monoclonal antibodies (mAbs) are a major class of biological medicine
with over 25 monoclonal antibodies registered for clinical use, and many more in
clinical trials. There are also antibody fragments, Fc fusions and antibody drug
conjugates that have been approved, and again many are in clinical development.
This is because of their specific action, and the reduced immunogenicity which can
now be achieved with the advent of completely human mAbs [88]. As mAbs and
related proteins are susceptible to degradation by aggregation and related particle
formation [89,90], lyophilisation is an appropriate formulation strategy when the
solution stability of the protein is low [20]. The addition of sugars (e.g. trehalose,
raffinose) during the freeze drying process can help to protect the native structure of
Key term:
Anydrobiotic organism : A microbe, animal or plant with a water content of
less than 1%.
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the antibody [91]. Currently there are a number of monoclonal antibody-based
products on the market (Table 3). These have been developed to provide a stable
antibody therapeutic on reconstitution with an aqueous-based medium. The resultant
medicine can be administrated as a subcutaneous (SC) injection, intravenous (IV)
infusion or intramuscular (IM) injection, with roughly equal numbers of products
using each route.
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Table 3: A list of commercially available freeze-dried therapeutic monoclonal antibodies.
Name mAbs Company Year Indication
Route of
administration
Strength Excipients
Herceptin
(Trastuzumab)
Humanised
IgG1k Genentech 1998
Metastatic breast
cancer
IV infusion 150 mg/vial, 21 mg/ml
after reconstitution
136.2 mg Trehalose, 3.36 mg L-histidine HCl,
2.16 mg L-histidine, 0.6 mg Polysorbate 20 to
be reconstituted in 7.2 ml of sterile water for
injection (SWFI), pH 6.0
Raptiva
(Efalizumab)
Humanised
IgG1k
Xoma and
Genentech
2003
(withdrawn
in 2009)
Psoriasis SC injection
150 mg/vial, 100
mg/ml after
reconstitution
123.2 mg Sucrose, 6.8 mg L-histidine HCl,
4.3 mg L-histidine, 3 mg Polysorbate 20,
reconstitute with 1.3 ml SWFI, pH 6.2
Remicade
(Infliximab)
Chimeric
IgG1k Centocor 1998
Rheumatoid arthritis
and Crohn’s disease IV infusion
100 mg/vial, 10 mg/ml
after reconstitution
500 mg Sucrose, 2.2 mg Monobasic sodium
phosphate, 6.1 mg dibasic sodium
phosphate, 0.5 mg Polysorbate 80,
reconstitute with 10 ml SWFI, pH 7.2
Synagis
(Palivizumab)
Humanised
IgG1k MedImmune 1998
Prevention for
Respiratory Syncytial
Virus
IM injection
50 and 100 mg/vial,
100 mg/ml after
reconstitution
For 50 mg vial – 40.5 mg Mannitol (5.6 %
w/v), 5.2 mg Histidine (47mM), 0.16 mg
Glycine (3.0 mM), reconstitute with 0.5 ml
SWFI, pH 6.0
Xolair
(Omalizumab)
Humanised
IgG1k
Genentech,
Novartis
2003 Asthma SC injection
202.5 mg/vial, 150
mg/1.2 ml after
reconstitution
145.5 mg sucrose, 2.8 mg L-histidine HCl, 1.8
mg L-histidine, 0.5 mg Polysorbate 20,
reconstitute with 1.4 ml SWFI, pH 6.0
Simulect
(Basiliximab)
Chimeric
IgG1k Novartis 1998
Prevention of organ
transplant rejection
IV infusion
10 or 20 mg/vial, 4
mg/ml after
reconstitution
For 10 mg vial – 10 mg Sucrose, 40 mg
Mannitol, 20 mg Glycine, 3.61 mg monobasic
potassium phosphate, 0.5 mg disodium
hydrogen phosphate, 0.8 mg NaCl,
reconstitute with 2.5ml SWFI
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2.3 PARTICLE TECHNOLOGY
Particle formulation is another approach that has attracted much attention for the
solidification of proteins in an effort to improve their stability and ease of
administration. It is hypothesised that this approach can capture protein molecules
within a polymer matrix, thus reducing molecular mobility [92]. Many strategies have
been applied to manufacture protein particles, each with its own limitations. These
include spray drying and emulsion preparations. Several products have made it into
the clinic using these strategies.
2.3.1 SPRAY DRYING
Spray drying is a conventional method commonly used in the food and
pharmaceutical industries to produce dry powders. This technology allows the large
scale production of biotherapeutics with high batch-to-batch reproducibility.
Typically a spray-drying system consists of an atomiser, drying chamber and cyclone
recovery unit, as illustrated in Figure 7 [93]. In brief, the drug solution is atomised
through small nozzles to generate fine droplets. Subsequently, hot dry air or an inert
gas (e.g. nitrogen) is blown over the formulation in the drying chamber. This rapidly
evaporates the solvent from the atomized droplets, yielding dry particles which are
separated by cyclone recovery and ultimately collected in a collecting tube [93].
Often the particles obtained are in the size range of 1-5 m, but smaller particles can
be obtained using different collecting tubes and spray drying conditions. Various
parameters including the inlet temperature (Tinlet), feeding rate, air flow rate, and
humidity can be controlled to alter the properties of the spray-dried particles.
Particularly when working with proteins, it is crucially important to understand and
optimise these factors (especially the temperatures applied). Limitations of the
technique include the fact that product recovery is often very challenging in early pre-
clinical work necessitating working with large amounts of material, which may not be
possible. Much spray drying is done using mixed aqueous solutions with for example
ethanol or acetone; these can cause protein degradation, and thus care is needed.
Surfactants are also often employed to enhance the process, and again may
compromise the integrity of protein actives.
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Figure 7: The apparatus used in spray drying.
Some processing parameters (e.g. heat, or the air-water interface) can have profound
effects on the in-process stability of proteins. Prinn et al. devised a statistical model to
determine the effect of processing parameters on spray-dried BSA particles prepared
on the lab scale [94]. In another study, the aggregation and deamidation of insulin was
found to rise significantly when the outlet temperature exceeded 120 ºC [95]. Heat
degradation can be mitigated if the contact time between the sprayed droplets and hot
air is as short as possible [96], but aggregation induced at the air-water interface
appears to be more pronounced under such conditions.
Mumenthaler et al. reported that spray-dried human growth hormone (hGH) exhibited
more aggregation when the atomisation rate was increased, ultimately yielding
approximately 67 % of soluble aggregates from the total spray dried particles [84].
Because of the surface-active properties of proteins, they tend to adsorb onto
boundaries, as previously described in in Section 2.2. Therefore, surfactants are often
added to prevent adsorption and aggregation [93]. It has been reported that the
formation of both insoluble and soluble aggregates of hGH was reduced 10-fold after
adding 0.1% (w/v) Tween 20 [84] during spray drying. This is consistent with the
results obtained by Abdul-Fattah et al. [97], showing that the total protein surface
accumulation was significantly decreased when Tween 20 was added during the
spray-drying of Met-hGH. Phospholipids exert the same effect with albumin, but care
must be taken when using ionic surfactants because they may alter the protein
structure [98].
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Dehydration in any drying method may perturb the native state of proteins, and so (as
in freeze-drying) sugars (e.g. di-and trisaccharides) and polyols are often added in
spray dried formulations to minimise destabilisation. By adding 10 – 20 % (w/w)
mannitol, the formation of soluble aggregates of a recombinant humanised anti-IgE
monoclonal antibody (rhuMabE25) during spray-drying was halved. The storage
stability at 5 ºC and 30 ºC also seemed to be improved compared to non-mannitol
formulations [99]. However, mannitol may undergo crystallisation during long term
storage, and potentially transforms into different polymorphic forms depending on the
temperature used in the drying process [100]. To avoid the possible inter-batch
variability which might result, sodium phosphate can be used to inhibit crystallisation
in spray-drying [99]. The presence of amino acid residues in proteins means that the
Maillard reaction can be a concern, particularly when they are heated. Hence, non-
reducing saccharides (e.g. trehalose and sucrose) are also often used in spray dried
formulations. This have the additional benefits of acting as glass forming agents,
limiting the molecular mobility of proteins which can contribute to their unfolding
[101], and also possibly stabilising the protein through the water replacement
mechanism [102,103]. Combinations of trehalose with other excipients (e.g. mannitol,
amino acids) have been applied to improve the physical stability of protein particles
[104].
Theoretically, low dynamic motion is believed to be responsible for the long term
stability of proteins embedded in a glassy matrix [101] (and indeed those which are
freeze dried). With low molecular weight excipients, spray-dried hGH showed greater
physical stability relative to analogous formulations prepared with high molecular
weight excipients. This is because lower molecular weight additives have higher true
densities, and true density is inversely proportional to the polymer’s free volume. A
lower free volume leads to a longer relaxation time (τ), contributing to resultant 
higher stability [97]. However, the interplay between a large number of factors
including process parameters and stabilisers needs be taken into account to determine
the ultimate stability of a spray dried protein formulation.
As protein adsorption is critical in spray-drying, the surface analysis of dry particles
(using e.g. specific surface analysis (SSA), or total protein surface accumulation) can
be useful to provide some insight into the stability of a spray dried formulation.
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Abdul-Fattah et al. conducted a study to examine the effect of spray-drying on the
stability of IgG1 (Medi-522) [105]. FTIR spectra showed that spray-drying can more
effectively preserve a native-like structure of the protein than other methods,
regardless of the formulation used. However, they found that IgG-sucrose
formulations (1:4 and 4:1) with a surfactant added were rather unstable at both 40 ºC
and 50 ºC. This is an unexpected result, as spray dried particles are generally expected
to be more stable if surfactants are added.
Spray dry proteins have been intensely investigated for pulmonary administration,
resulting in one commercially available product. The process is capable of producing
‘inhalable’ micron sized-particles if the processing parameters are appropriately
controlled. A high atomising flow rate and low protein concentration in the
formulation gives rise to particles with mass median aerodynamic diameters
(MMAD) in the micron range [94,95]. The nozzle can also be modified to improve
particle size. For example, ultrasonic or two-fluid nozzles are found to generate more
uniform sized particles [106,107]. The additives discussed earlier also assist particle
formation and enhance aerosolisation properties, in addition to their roles in protein
stabilisation.
Healy et al. have explored the use of spray drying to prepare spray-dried sugar/protein
composites. Using an optimised solvent ratio of 80:20 methanol : butyl acetate, spray-
dried trehalose was found to form porous particles with low MMAD (3.14 ± 0.62
μm), and lower bulk and tap densities than similar non-porous formulations (see 
Figure 8) [108]. The model enzyme lysozyme could be incorporated into the spray-
dried particles by simply making a mixed solution of the protein and sugar in 80:20
methanol : butyl acetate. Its specific biological activity was, within experimental
error, identical to the lysozyme prior to processing (ranging from 93.5 ± 4.4 % to
103.9 ± 4.4 %). This study thus offers a composite system with ideal properties for
protein delivery via the pulmonary route. In another study,
dipalmitoylphosphatidylcholine (DPPC) could be combined with albumin to yield
Key term:
Relaxation time: The period required for a macromolecule to rearrange itself
to occupy the free volume (i.e. the unfilled space) in a formulation.
25
porous particles by spray-drying from an ethanol-water system [109]. L-leucine, an
amino acid often added to improve powder flowability, can also be applied to
encapsulate proteins [104].
Figure 8: Scanning electron microscopy images of spray-dried trehalose prepared using MeOH : butyl
acetate (80:20). Reproduced with permission from ref. [108]. Copyright Elsevier 2011.
Commercial application: Insulin
Only one spray-dried protein therapeutic has completed clinical trials and reached the
marketplace. This is Exubera®, an insulin inhaler developed by Pfizer. The
formulation developed allowed insulin stabilisation at room temperature and showed
excellent product performance in term of dose reproducibility and efficacy [110].
However, this product unfortunately had to be withdrawn from the market because of
poor sales [111]. More recently, MannKind Corporation has developed a technology
platform (Technosphere®) to deliver a range of proteins via the pulmonary route
[112]. The technology uses a novel excipient fumaryl diketopiperazine (FDKP) to
form microparticles in this technology. An ultra-rapid insulin formulation, Afrezza®,
has been developed from this pipeline and is in late stage clinical trials.
Key term:
Inhalable micron sized particles : Formulations with particles whose size
ranges from 1 – 10 μm. 
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2.3.2 EMULSION METHODS
Emulsion methods have been extensively investigated in pharmaceutical research for
preparing polymeric particles (often known as microspheres) both for small-molecule
active ingredients (APIs) and therapeutic proteins. The process can be undertaken
with a wide range of polymers, and is relatively easy to up-scale (although
sterilisation can be challenging). Emulsion fabrication generally involves two steps:
emulsification and solvent removal. Initially, a stable single or double emulsion is
required to obtain protein - polymer oil droplets dispersed in a continuous aqueous
phase. This can subsequently be emulsified by adding an emulsifier or through
agitation (see Figure 9). It should be noted that these processes have significant
potential to damage a protein through shear forces, the presence of a non-aqueous co-
solvent, etc: hence, very careful control of processing parameters is required, together
with robust testing of a protein’s efficacy post-emulsification.
Although the oil-in-water method (o/w) or double emulsion (w/o/w) is most widely
employed, it often results in low encapsulation efficacy as proteins can diffuse from
the oil phase to the continuous aqueous phase [113]. Additionally, proteins are prone
to aggregation in these approaches because of the existence of an aqueous/organic
interface, and exposure to the organic solvent. The shear forces present during
emulsification also cause proteins to unfold and to aggregate. Modified emulsion
systems in which solid proteins in are dispersed in an organic solvent, such as solid-
in-oil-in-water (s/o/w) or solid-in-oil-in-oil (s/o/o) approaches, can ameliorate the
aggregation and initial burst release which are often observed in the w/o/w method
[114].
In the second step of an emulsification process, the solvent is removed and the
droplets are allowed to solidify. Solvent transfer is a critical factor in this step because
it can affect the morphology, entrapment efficacy and release profile of the particles.
Evaporation by heating is commonly used to eliminate solvent from the emulsion
(great care must be taken to avoid compromising the protein during heating). Rosca et
al. conducted a mechanistic study to examine particle formation by solvent
evaporation from both single and double emulsions of poly(lactic-co-glycolic acid)
(PLGA) [115]. It was observed that a thin layer of the inner oil phase forms around
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the surface of the particles upon solvent removal, which is linked to burst release. In
the case of a double emulsion, the inner droplets may aggregate and form holes, again
contributing to burst release.
Other than using heat, the solvent in an emulsion can also be removed by using other
techniques such as supercritical fluid (SCF) technology or an electric field: these
methods have recently been reviewed elsewhere [116]. SCFs can be used as drying
media or antisolvents, and expose proteins to relatively low stress conditions [117].
Solvent evaporation using an electric field can also avoid the use of heat. Both these
approaches therefore offer advantages over traditional heating approaches when
working with protein formulations. Following solvent removal, the protein particles
are collected and sterilised.
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Dry microspheres (polymer particles)
Figure 9: A flow diagram depicting polymer/protein particles (or microspheres) prepared by the
emulsion method.
Single emulsion method Double emulsion method
Stirring
O/W
emulsion
W2/O/W1
emulsion
Proteins + polymer
in organic solvents
(dispersed phase, O)
Proteins +
buffer solution (W1)
Polymer +
organic solvents (O)
Sonication
W1/O emulsion
Continuous phase (W2)
Solvent removal
Centrifugation / drying /
lyophilisation
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Poly(lactic acid) (PLA) Poly(glycolic acid) (PGA) Polyanhydrides
Poly(D,L-lactide-co-glycolide) (PLGA) Polycarbonate
Poly(carprolactone) (PCL) Polyphosphoesters (PPE)
Poly(orthoester) IV (POE IV)
Figure 10: Commercial synthetic polymers used for microsphere formulation.
Polymer selection is another perspective which has a significant influence on the
properties of particles prepared through the emulsion route. In addition, some
polymers, such as PLGA, may be incompatible with a particular protein of interest. In
general, biodegradable polymers are most appropriate for micro sized carrier
formulations, aiding their biocompatibility. A range of both synthetic polymers and
natural polymers have been explored for protein microsphere preparation. Natural
polymers display many advantages such as being processable under mild conditions,
ideal for generating protein formulations, and biocompatibility. However, challenges
with scalability have limited their utilisation [118]. Natural polymers which have been
explored include sodium alginate [119], pullulan [120], hyarulonic acid [121] and
chondroitin sulfate [122].
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The use of synthetic polymers thus appears to be a more viable option. Many types of
polymer have been commercialized, as depicted in Figure 10. Polyesters (e.g. POEs,
PLGA and PCL) are the most commonly used for biomedical applications; they
degrade in in vivo by undergoing ester hydrolysis into monomers [123]. Varying the
monomer ratio or modification of the polymer backbone can modulate the release rate
of the drug encapsulated in the matrix. For instance, the POE IV matrix erodes on the
surface with no resultant change in local pH, enabling controlled drug release [124].
In terms of stability, some studies have examined the structural conformation of
bioactive proteins in encapsulated biodegradable polymers. FTIR spectra indicate that
the characteristic amide I and II bands for insulin extracted from PLGA
microparticles are relatively close to those of native insulin [125]. DSC thermograms
show that the melting point of insulin increases from 91.08 ºC to 104.4 ºC upon
encapsulation, thus indicating an enhancement of stability in the microcapsule
formulation. Recombinant hGH released from PLGA microparticles after 28 days
remained active and was able to stimulate Nb2 cell proliferation [126].
Aggregation during in vitro study is a major challenge encountered when working
with biodegradable particles. The protein is vulnerable to aggregation if there is an
interface present; hydrophobic/hydrophilic interfaces between protein and polymer
may also result in aggregation. Taluja et al. deduced that the presence of an acidic
environment during dissolution is a major cause of aggregation for several protein
drugs, especially in polyester matrices [113]. Many strategies, such as changing the
parameters used in emulsion preparation or adding stabilisers, have been proposed to
improve protein stability on storage and in physiological media [124,127].
Commercial application: Lupron Depot® LH-RH analogue-sustained release
injectable microspheres
The use of polymeric carriers for peptide formulations has attracted much attention
because the drug release can be prolonged, which can eliminate the need for frequent
dosing. PLGA is the most widely explored biodegradable polymer and is clinically
approved by the Food and Drug Administration (FDA). There are four PLGA-based
peptide formulations currently available, detailed in Table 4. It should be noted that in
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the case of such small peptides there is no real tertiary structure, and thus formulation
into microspheres is less problematic than is the case with larger proteins.
Considering the latter, only Nutropin Depot®, a 1 month sustained release
formulation of the recombinant human growth hormone (rhGH) contains a bioactive
protein incorporated into microspheres. In addition LB03002, a once-weekly rhGH
microsphere medicine formulated using sodium hyaluronate, has completed phase 3
clinical trials [121,128].
Lupron Depot® contains leuprolide acetate, a synthetic nonapeptide analogue of
luteinizing hormone releasing hormone (LH-RH)) shown in Figure 11. It was
developed by Takeda using poly(lactic acid) (PLA) or PLGA microparticles as the
delivery platform. It has been approved to treat prostate cancer, endometriosis and
precocious puberty. The treatment for such diseases usually requires frequent
injections, and to improve patient comfort and convenience monthly and three-
monthly release formulations were developed using the w/o/w technique [129]. The
differences between the monthly and three-month formulations lie in the drug
loading, type of polymer and preparation procedure, and are illustrated in Figure 12.
The study of in vivo release from both formulations showed that PLA microspheres
exhibited continuous release over 3 months. In contrast, depots based on PLGA
release over a shorter period of 1 month. In both preparations, the matrix initially
exhibits protein diffusion from the surface, followed by further release mediated by
polymer erosion. Miller et al. pointed out that the latter phase is key to controlled
drug release, and the inclusion of glycolic monomers increases the rate of erosion
[130]. Okada has suggested that the long hydrocarbon chains of the polymers (PLGA
or PLA), in which the terminal anionic groups interact with the peptide serve as a
diffusion barrier for the protein, therefore retarding the release [129]. This explains
why PLGA (75:25) (lactic:glycolic) and PLA were chosen to develop once-a-month
and three-monthly formulations respectively. Currently, there are eight commercial
products developed using this platform; they are available in a ready-to-use two part
compartmentalized syringe in which reconstituted microspheres are separated from
the dispersing solution until immediately before use [124].
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Table 4: A list of commercially available peptide formulations based on injectable PLGA microspheres. Adapted from refs. [123,124].
Trade name ( Drug) Product Polymer Indication Methods Company
Lupron Depot ® (Leuprolide acetate) Lupron Depot, 7.5 mg (1-month)
Lupron Depot, 3.75 mg (1-month)
Lupron Depot, 11.25 mg (3-month)
Lupron Depot, 22.5 mg (3-month)
Lupron Depot, 30 mg (4-month)
Lupron Depot, 45 mg (6-month)
Lupron Depot PED, 7.5 mg (1-month)
Lupron Depot PED, 11.25 mg, 15 mg (3-month)
PLGA
PLA
PLGA
PLA
Palliative treatment of advanced
prostatic cancer
Endometriosis
Palliative treatment of advanced
prostatic cancer
Precocious puberty in children
Emulsion Takeda
Sandostatin ® LAR ®
(Octreotide acetate)
Sandostatin LAR Depot (1 month) PLGA Acromegaly, Carcinoid tumors,
VIPomas
Emulsion Novartis
Trelstar™ Depot (Triptorelin
pamoate)
Trelstar LA 3.75 mg (1-month) PLGA Palliative treatment of advanced
prostatic cancer
Spray-drying Watson
Pharma
Bydureon (Exenatide) Bydureon (weekly) PLGA Type II diabetes Emulsion Amyllin/ Eli
Lilly/
Alkermes
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Figure 11: The amino acid sequence of leuprolide.
Figure 12: A schematic illustrating the preparation of the once-a-month and three-monthly Lupron
Depot® formulations using the emulsion method. Adapted from ref. [129].
Three-monthly PLA microspheres
of leuprolide acetate
Monthly PLGA microspheres
of leuprolide acetate
Leuprolide
acetate 450 mg
+ Gelatin
solution 0.5 ml
PLGA (75/25)-Mw14000 4 g
/ dichloromethane 5 ml
W/O emulstion
0.25% PVA
aqueous
solution 100ml
W/O/W
emulsion
Leuprolide
acetate 550 mg
PLA-Mw 15000
4 g /
dichloromethane
7.5 ml
W/O emulstion
0.25% PVA
aqueous
solution 100ml
W/O/W
emulsion
Solvent evaporation
Lyophilisation
Polymer (PLGA, PLA)
Leuprolide acetate
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3. FUTURE PERSPECTIVE
3.1 PROTEIN STABILISATION IN NANOFIBRES
The previous sections have highlighted the solidification techniques that are currently
used to manufacture protein therapeutics. It appears from the trend of publications in
the literature and the number of available commercial products that protein
encapsulation in a polymer-based solid is growing in popularity relative to
crystallization approaches. The former provides additional advantages including
scalability, ready to use dosage forms and versatile drug administration. Advances in
nanomaterials engineering are attracting growing interest in the biomedical research
field, and could offer new opportunities to enhance the stability of biotherapeutics.
However, the difficulty of controlling bottom-up processes and the high
manufacturing costs involved present hurdles to industrial application.
Electrospinning (ES) is a facile ‘top-down’ approach to the production of
nanostructured materials which has recently attracted increasing interest in the
preparation of protein formulations. It allows the fabrication of a wide range of
materials using synthetic polymers, carbohydrates, or proteins. In the simplest
solution ES, a polymer and functional component (e.g. a small molecule drug or a
protein) are dissolved in a volatile solvent, and electrical energy used to evaporate the
solvent [131]. The polymer solution is ejected from a metal-tipped syringe at a
controlled rate towards a metal collector plate. A high voltage is applied between the
two, which causes rapid evaporation of the solvent and the production of polymer
particles on the μm scale .This process occurs very rapidly, yielding one-dimensional 
solid fibres. The process can be conducted at room temperature, precluding thermally-
induced protein denaturation. A proof of concept study indicated that proteins can be
processed by ES and remain in the native state [132].
As for the other techniques discussed above, however, the interplay of material
properties and processing parameters during ES is very important, and may
complicate the use of ES in the large-scale manufacturing of protein formulations.
Batch-to-batch or intra-batch inconsistency in the size and shape of the fibres
produced is often observed, and can influence the functionality of the materials
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produced. ES uses organic solvents, which may have an effect on protein folding, and
polymer-protein interactions must also be understood. Ideally, water would be used
for ES to prevent protein denaturation, but the use of aqueous based polymer
solutions is generally not practical because of water’s high surface tension, high
boiling point and high dielectric constant. To achieve the effective evaporation of
water in an ES process it is generally necessary to use heat, which of course
introduces other protein degradation possibilities. These issues can be minimised to
some extent by adding surfactants or using SCF as a solvent.
The most simple one-fluid electrospinning process is thus probably not suitable for
the development of protein formulations. Multicomponent electrospun fibres are
more promising, however, and have the potential to protect proteins from physical
stress. A process known as coaxial ES can fabricate core-shell structured fibres by
simultaneously co-spinning sheath and core polymer fluids. The apparatus is the same
as used in single-fluid ES except that a concentric spinneret with one needle nested
inside another (a “coaxial spinneret”) is used. This is depicted in Figure 13. A protein
solution is generally loaded in the core, and surrounded by an outer polymer layer. It
has been shown that lysozyme remains in its native structural conformation after
being encapsulated in the core of PCL-based core-shell fibres, and is slowly released
over 13 days [133]. These results are depicted in Figure 14. The same study suggested
that other stabilisers (e.g. PEG or sugars) may be incorporated to enhance protein
stability. A similar core-shell structure can be also achieved through the ES of
emulsions. Protein droplets dispersed in a polymer solution can be processed by ES,
which typically results in fibres with a protein-based core and polymer shell [134].
Microfluidic technology can also be applied to produce composites which contain
both fibres and protein encapsulated in microbubbles [135], as shown in Figure 15.
Electrospun nanofibres are being increasingly explored in a variety of medical areas,
such as in tissue engineering. This is attributed to the similarities in structure between
Key term:
Multicomponent fibres: Electrospun fibres containing more than one functional
component.
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electrospun fibre products and the natural extracellular matrix (ECM); the latter plays
an important role in cell adhesions. ES fibres have also been widely explored in the
development of drug delivery systems for a range of different purposes including as
wound-healing dressings, implants or controlled release carriers: these were reviewed
recently [131]. ES protein formulations have featured in a number of studies: for
instance, the successful sustained release of vascular endothelial growth factors
(VEGF) from PLGA/dextran core-shell fibres suggest the potential to fabricate
protein loaded scaffolds with activity lasting beyond 28 days [136]. This is highly
attractive in the development of formulations for protein therapeutics with long-
lasting action, required in areas such as regenerative medicine and hormone
replacement therapy.
Figure 13: a) a schematic diagram of the coaxial electrospinning apparatus; b) a photo of the droplets
ejected from the coaxial spinneret. The core fluid is pink, and the shell colourless.
a) b)
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Figure 14: CD spectra of native lysozyme and the protein released from PCL core-shell fibres,
showing that the structural integrity is retained throughout electrospinning and drug release.
Reproduced with permission from ref. [133]. Copyright Elsevier 2005.
Figure 15: The product of combining electrospinning and microfluidics, showing the presence of
microbubbles connected by fibres. Taken with permission from ref. [135]. Copyright Elsevier 2012.
3.2 OTHER TECHNOLOGIES
Protein therapeutics are rapidly evolving and becoming even more complex.
Important classes of proteins such as monoclonal antibodies, cytokines and enzymes
have become clinical mainstays, and in several cases, first line treatments. New
classes of therapeutic proteins have achieved clinical validation including multifunc-
tional proteins (e.g. bispecific antibodies) and immunoconjugates (e.g. antibody drug
conjugates). Other types of multifunctional proteins and new product motifs are
expect to continue to emerge. One example is antibody mimetics: these possess the
binding attributes of monoclonal antibodies, but may also prove to be more stable
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[137]. More stable therapeutic proteins and hybrid protein formats will drive the
development of new dosage forms. The use of new excipients [138] that inhibit
protein aggregation will also be critical to develop stable dosage forms of protein
therapeutics.
There remains a need for solid-state forms of protein therapeutics that can be stored
without a cold chain. When considering all the manufacturing steps to produce such a
therapeutic, the costs involved with the processes used to formulate and fabricate the
final dosage form are considerable. Ensuring that these processes are scalable,
reproducible and cost effective are key goals that are being targeted early in
development. Whilst the processes described in this review to make solid state forms
of protein therapeutics will continue to evolve, computational modeling strategies are
being increasingly employed, along with high throughput strategies, in efforts to
identify optimal process parameters early in development.
4. CONCLUSIONS
The development of solid protein formulations has provided great benefit in
enhancing their stability, resulting in a range of applications and marketed products.
A range of methods have been explored to achieve this goal including crystallization,
freeze-drying, and encapsulation into a solid (usually polymer-based) matrix by
spray-drying or emulsion routes. In all cases, great care must be taken during the
formulation process to ensure that processing parameters, or the interplay between
multiple parameters, do not compromise the stability of the protein in the final
formulation. In addition to the current routes, there exist exciting future possibilities
for developing new protein/polymer composites, including electrospinning. However,
for these techniques also a careful consideration of how the processing will influence
the protein structure is required to ensure efficacious products are developed.
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Executive summary
Stability of solid protein therapeutics
 The formulation of proteins in the solid state can preclude or retard the
hydrolytic degradation which is commonly observed with liquid formulations
during handling and storage.
Solidification techniques for proteins
 Crystallisation, freeze-drying and particle technology are used to manufacture
solid protein products with different drug delivery applications. Care must be
taken when realising the processes, however, in order not to inadvertently
cause damage to the protein.
 These solid state formulations can yield controlled drug release resulting for
instance in reduced dosing frequencies, as well as providing protein stability
enhancement.
Multicomponent electrospun nanofibres for protein stabilization
 Co-axial electrospinning allows the fabrication of multicomponent nanoscale
fibres, and has great potential in the development of solid state protein
formulations, both for stability enhancement and release modulation.
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